News

FDA Oncology Director to Address Advanced Practitioners About Expediting the Drug Development Process

Published by Conor Lynch 6 years ago

Lawrenceville, NJ (PRWEB) September 07, 2017--The Advanced Practitioner Society for Hematology and Oncology (APSHO) announced today that Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence (OCE), will be the keynote speaker at the Fifth Annual JADPRO Live at APSHO conference on November 3 in Houston, Texas. His talk will focus on the latest emerging initiatives in the quest to expedite the drug development process.

The OCE leverages the combined skills of the FDA’s regulatory scientists and reviewers with expertise in drugs, biologics and devices to advance the development of novel cancer products. Dr. Pazdur is responsible for leading the effort to develop and execute an integrated regulatory approach to enhance the cross-center coordination of oncology product clinical review. His keynote address will focus on how the changing landscape of oncology drug development and approval will affect advanced practice. Conference attendees will gain valuable insights into FDA regulatory principles with respect to trial design and accelerated approval programs.

“We are honored to have Dr. Pazdur address the APSHO membership as well as other advanced practitioners attending the conference,” commented Pamela Hallquist Viale, RN, MS, CNS, ANP, the President of the APSHO Board of Directors. “Advanced practitioners have a keen interest in helping improve the lives of patients with cancer, and the opportunity to learn from Dr. Pazdur shouldn’t be missed”

Dr. Pazdur has long been a champion of the advanced practitioner. His late wife, Mary Pazdur, was a nurse practitioner and a driving force for the creation of the Journal of the Advanced Practitioner in Oncology (JADPRO), the publication that inspired the development of the live conference.

“As a seasoned oncology advanced practitioner, Mary was instrumental in helping to refine the concept behind the creation of JADPRO,” said Jack Gentile, Chairman of Harborside Press, the journal’s publisher. “She validated the need for a journal that would speak specifically to the needs of this highly skilled, highly trained set of oncology professionals.”

To learn more about the conference, please visit JADPROLive.com.

About Harborside

Harborside is a medical communications company based in Huntington, New York. It is the publisher of the Journal of the Advanced Practitioner in Oncology (JADPRO), The ASCO Post, JNCCN—Journal of the National Comprehensive Cancer Network, and the Journal of Oncology Practice. Harborside designs educational resources for practicing nurse practitioners, physician assistants, pharmacists, and other advanced practitioners by publishing JADPRO, organizing the JADPRO Live at APSHO conferences and providing the management services for the Advanced Practitioner Society for Hematology and Oncology. Harborside also manages the advertising sales for ASCO’s suite of publications, including the Journal of Clinical Oncology (JCO), the Journal of Global Oncology, JCO Clinical Cancer Informatics, and JCO Precision Oncology.

About JADPRO Live at APSHO 

JADPRO Live at APSHO is a medical conference inspired by the Journal of the Advanced Practitioner in Oncology. This year’s meeting will take place from November 2–5, 2017 at the Houston Marriot Marquis.

About APSHO 

The Advanced Practitioner Society for Hematology and Oncology (APSHO) is a society for advanced practitioners—nurse practitioners, clinical nurse specialists, physician assistants, pharmacists, and other oncology health-care professionals. The mission of APSHO is to actualize oncology patient care that is high quality, cost effective, and delivered through collaborative practice models by optimizing the role of the advanced practitioner as an integral member of the care team.